1 Winn, B., Whitaker, D., Elliott, D. B. & Phillips, N. J. Factors affecting light-adapted pupil size in normal human subjects. Invest Ophthalmol Vis Sci 35, 1132-1137 (1994).
2 Lussier, B. L., Olson, D. M. & Aiyagari, V. Automated Pupillometry in Neurocritical Care: Research and Practice. Curr Neurol Neurosci Rep 19, 71, doi:10.1007/s11910-019-0994-z (2019).
3 Frost, S. et al. Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. J Ophthalmol 2017, 7935406-7935406, doi:10.1155/2017/7935406 (2017).
4 Hall, C. A. & Chilcott, R. P. Eyeing up the Future of the Pupillary Light Reflex in Neurodiagnostics. Diagnostics (Basel, Switzerland) 8, doi:10.3390/diagnostics8010019 (2018).
5 Wu, S. Z., Masurkar, A. V. & Balcer, L. J. Afferent and Efferent Visual Markers of Alzheimer’s Disease: A Review and Update in Early Stage Disease. Front Aging Neurosci 12, 572337, doi:10.3389/fnagi.2020.572337 (2020).
6 Giza, E., Fotiou, D., Bostantjopoulou, S., Katsarou, Z. & Karlovasitou, A. Pupil light reflex in Parkinson's disease: evaluation with pupillometry. The International journal of neuroscience 121, 37-43, doi:10.3109/00207454.2010.526730 (2011).
7 Giza, E. et al. Pupillometry and 123I-DaTSCAN imaging in Parkinson's disease: a comparison study. The International journal of neuroscience 122, 26-34, doi:10.3109/00207454.2011.619285 (2012).
8 Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30, 1591-1601, doi:10.1002/mds.26424 (2015).
9 Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25, 2649-2653, doi:10.1002/mds.23429 (2010).
10 Fotiou, D. F. et al. Effect of age on pupillary light reflex: evaluation of pupil mobility for clinical practice and research. Electromyogr Clin Neurophysiol 47, 11-22 (2007).
11 Guillon, M. et al. The Effects of Age, Refractive Status, and Luminance on Pupil Size. Optom Vis Sci 93, 1093-1100, doi:10.1097/opx.0000000000000893 (2016).
12 Bye, C. E. et al. Changes in the human light reflex as a measure of the anticholinergic effects of drugs. A comparison with other measures. Eur J Clin Pharmacol 15, 21-25, doi:10.1007/bf00563554 (1979).
13 Chen, Z., Li, G. & Liu, J. Autonomic dysfunction in Parkinson’s disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiology of Disease 134, 104700, doi:https://doi.org/10.1016/j.nbd.2019.104700 (2020).
14 Bartosova, O. et al. Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients. Journal of neural transmission (Vienna, Austria : 1996) 125, 699-703, doi:10.1007/s00702-017-1829-1 (2018).
15 Jain, S. et al. Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson's disease. Parkinsonism Relat Disord 17, 119-122, doi:10.1016/j.parkreldis.2010.11.005 (2011).
16 Yang, Laura L., Niemann, Claus U. & Larson, Merlin D. Mechanism of Pupillary Reflex Dilation in Awake Volunteers and in Organ Donors. Anesthesiology 99, 1281-1286, doi:10.1097/00000542-200312000-00008 (2003).
17 Micieli, G., Tosi, P., Marcheselli, S. & Cavallini, A. Autonomic dysfunction in Parkinson's disease. Neurol Sci 24 Suppl 1, S32-34, doi:10.1007/s100720300035 (2003).
18 Forno, L. S. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55, 259-272, doi:10.1097/00005072-199603000-00001 (1996).
19 Yeh, T. L. et al. Correlation between striatal dopamine D2/D3 receptor binding and cardiovascular activity in healthy subjects. Am J Hypertens 19, 964-969, doi:10.1016/j.amjhyper.2006.03.005 (2006).
20 van Deursen, D. N., van den Heuvel, O. A., Booij, J., Berendse, H. W. & Vriend, C. Autonomic failure in Parkinson’s disease is associated with striatal dopamine deficiencies. Journal of Neurology 267, 1922-1930, doi:10.1007/s00415-020-09785-5 (2020).
21 Wang, Y. et al. Parasympathetic Nervous System Dysfunction, as Identified by Pupil Light Reflex, and Its Possible Connection to Hearing Impairment. PLoS One 11, e0153566, doi:10.1371/journal.pone.0153566 (2016).
22 Micieli, G. et al. Disordered pupil reactivity in Parkinson's disease. Clin Auton Res 1, 55-58, doi:10.1007/bf01826058 (1991).
23 Dietz, J., Bradley, M. M., Okun, M. S. & Bowers, D. Emotion and ocular responses in Parkinson's disease. Neuropsychologia 49, 3247-3253, doi:10.1016/j.neuropsychologia.2011.07.029 (2011).
24 Armstrong, R. A. Oculo-Visual Dysfunction in Parkinson's Disease. J Parkinsons Dis 5, 715-726, doi:10.3233/jpd-150686 (2015).
25 Fotiou, D. F. et al. Cholinergic deficiency in Alzheimer's and Parkinson's disease: evaluation with pupillometry. International journal of psychophysiology : official journal of the International Organization of Psychophysiology 73, 143-149, doi:10.1016/j.ijpsycho.2009.01.011 (2009).
26 Granholm, E. et al. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. International journal of psychophysiology : official journal of the International Organization of Psychophysiology 47, 95-115, doi:10.1016/s0167-8760(02)00122-8 (2003).
27 Chougule, P. S., Najjar, R. P., Finkelstein, M. T., Kandiah, N. & Milea, D. Light-Induced Pupillary Responses in Alzheimer's Disease. Frontiers in neurology 10, 360, doi:10.3389/fneur.2019.00360 (2019).
28 Zarow, C., Lyness, S. A., Mortimer, J. A. & Chui, H. C. Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases. Archives of Neurology 60, 337-341, doi:10.1001/archneur.60.3.337 (2003).
29 Mannelli, M. et al. In vivo evidence that endogenous dopamine modulates sympathetic activity in man. Hypertension 34, 398-402, doi:10.1161/01.hyp.34.3.398 (1999).
30 Goldstein, D. S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2, 669-676, doi:10.1016/s1474-4422(03)00555-6 (2003).
31 Skorvanek, M. et al. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. Mov Disord Clin Pract 4, 536-544, doi:10.1002/mdc3.12476 (2017).
32 Chung, S. J., Lee, J. J., Lee, P. H. & Sohn, Y. H. Emerging Concepts of Motor Reserve in Parkinson’s Disease. JMD 13, 171-184, doi:10.14802/jmd.20029 (2020).